TABLE 2.

Ventilatory parameters measured during the hypoxic HCVR test.

	Drug	Baseline PETCO2		+2 mmHg PETCO2		+4 mmHg PETCO2		+6 mmHg PETCO2
		Pre	Post	Pre	Post	Pre	Post	Pre	Post
V̇I	Losartan	16 ± 2	17 ± 1	37 ± 5	50 ± 4	45 ± 4	59 ± 4	50 ± 5	61 ± 3
(l/min)	Placebo	15 ± 1	18 ± 1	41 ± 5	52 ± 4	47 ± 5	60 ± 5	54 ± 5	62 ± 4
LSM		18 ± 2		47 ± 2*		55 ± 2*†		59 ± 3*†⁣‡
				Drug: P = 0.3		Stage: P < 0.001		Drug*Stage: P = 0.6
PETO2	Losartan	92 ± 2	96 ± 1	49 ± 1	50 ± 0	49 ± 0	50 ± 0	49 ± 1	49 ± 0
(mmHg)	Placebo	92 ± 2	98 ± 1	50 ± 1	51 ± 1	50 ± 1	50 ± 1	50 ± 1	50 ± 1
LSM		92 ± 1		50 ± 1*		50 ± 0*		49 ± 1*
				Drug: P = 0.03		Stage: P < 0.001		Drug*Stage: P = 1.0
PETCO2	Losartan	40 ± 1	35 ± 0	42 ± 1	37 ± 1	44 ± 1	39 ± 1	46 ± 1	41 ± 1
(mmHg)	Placebo	41 ± 1	37 ± 1	43 ± 1	39 ± 1	45 ± 1	41 ± 1	47 ± 1	43 ± 1
LSM		39 ± 1		41 ± 1*		43 ± 1*†		45 ± 1*†
				Drug: P = 0.03		Stage: P < 0.001		Drug*Stage: P = 0.6
MAP	Losartan	82 ± 2	86 ± 3	87 ± 3	94 ± 3	90 ± 3	96 ± 3	91 ± 3	99 ± 4
(mmHg)	Placebo	87 ± 3	88 ± 2	94 ± 3	98 ± 2	98 ± 3	99 ± 3	102 ± 4	101 ± 3
LSM		86 ± 1		94 ± 2*		97 ± 2*		99 ± 2*†
				Drug: P = 0.3		Stage: P< 0.001		Drug*Stage: P = 0.9
HR	Losartan	63 ± 2	60 ± 2	77 ± 2	77 ± 2	80 ± 2	82 ± 2	82 ± 2	82 ± 2
(bpm)	Placebo	63 ± 2	60 ± 3	79 ± 2	82 ± 2	82 ± 2	82 ± 2	86 ± 2	88 ± 2
LSM		61 ± 1		78 ± 2*		81 ± 2*		83 ± 2*†
				Drug: P = 0.7		Stage: P < 0.001		Drug*Stage: P = 0.2

All values are mean ± SEM. *Indicates a significant difference from baseline (p < 0.05); ^†Significant difference from +2 mmHg (p < 0.05); ^‡significant difference from +4 mmHg (p < 0.05). LSM, least mean squares; V̇_I, minute ventilation; P_ETO₂, end-tidal oxygen; P_ETCO₂, end-tidal carbon dioxide; MAP, mean arterial pressure; HR, heart rate. Bolded values indicate significant main effects.